Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses
This phase 1 clinical trial demonstrates that controlled human challenge with dengue virus reveals how pre-existing antibody profiles, particularly those targeting non-structural protein 1, dictate infection outcomes by either driving pathogenic enhancement or enabling sterilizing immunity through balanced, enduring T and B cell responses.
Odio, C. D., Aogo, R. A., Firdous, S., Voirin, C., Blanco-Rivera, S., Lowman, K. E., Asante, N., Broderson, Y., Konda, K., Hasund, C. M., Martinez-Perez, A., Mpingabo, P. I., Law, M., Jarvis, C., Call (…)2026-03-27📄 infectious diseases